Literature DB >> 30972631

Are We Choosing Surveillance Imaging in Gastric and Pancreatic Cancers Wisely? A Population-Based Study.

David L Chan1, Matthew Cheung1,2,3, Craig C Earle1,2, Natalie Coburn1,2, Nicole Mittmann2,3, Farah Rahman2, Ning Liu2, Simron Singh4,5,6.   

Abstract

BACKGROUND/
OBJECTIVE: Although gastric and pancreatic cancers are aggressive, there is no evidence that early detection of recurrence improves overall survival. We aimed to measure the frequency of surveillance imaging in patients after curative resection for gastric and pancreatic cancers.
METHODS: We performed a population-based cohort study on patients in Ontario, Canada, with a first diagnosis of gastric and pancreatic cancer in 2003-2013. Health administrative databases were linked using unique encoded identifiers to record demographics, imaging frequency, and health resource utilization.
RESULTS: The cohort comprised 2930 patients (2151 gastric, 779 pancreatic). The median age was 69 (38% female). The cumulative incidence of CT imaging overall was 74.3% after 1 year and 82.8% by 3 years. Imaging was more likely for pancreatic cancer compared to gastric cancer (p < 0.0001). On multivariate analysis, imaging was less likely for females and older patients and varied significantly by health district. Imaging frequency increased over the study period.
CONCLUSIONS: Significant and increasing numbers of patients received surveillance imaging after resection of gastric or pancreatic cancers despite lack of data to show its benefit. This data shows the need for the Choosing Wisely Canada recommendations (published after the study period) and serve as a baseline for future analyses.

Entities:  

Keywords:  Choosing wisely; Gastric cancer; Pancreatic cancer; Surveillance

Mesh:

Year:  2020        PMID: 30972631     DOI: 10.1007/s12029-019-00235-8

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  21 in total

1.  Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  M Ducreux; A Sa Cuhna; C Caramella; A Hollebecque; P Burtin; D Goéré; T Seufferlein; K Haustermans; J L Van Laethem; T Conroy; D Arnold
Journal:  Ann Oncol       Date:  2015-09       Impact factor: 32.976

2.  An application of capture-recapture methods to the estimation of completeness of cancer registration.

Authors:  S C Robles; L D Marrett; E A Clarke; H A Risch
Journal:  J Clin Epidemiol       Date:  1988       Impact factor: 6.437

Review 3.  Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology.

Authors:  Margaret Tempero; J Pablo Arnoletti; Edgar Ben-Josef; Pankaj Bhargava; Ephraim S Casper; Paula Kim; Mokenge P Malafa; Eric K Nakakura; Stephen Shibata; Mark Talamonti; Hanlin Wang; Christopher Willett
Journal:  J Natl Compr Canc Netw       Date:  2007-11       Impact factor: 11.908

Review 4.  Follow-up: the evidence.

Authors:  Domenico D'Ugo; Alberto Biondi; Andrea Tufo; Roberto Persiani
Journal:  Dig Surg       Date:  2013-07-18       Impact factor: 2.588

5.  Using the Johns Hopkins Aggregated Diagnosis Groups (ADGs) to predict mortality in a general adult population cohort in Ontario, Canada.

Authors:  Peter C Austin; Carl van Walraven; Walter P Wodchis; Alice Newman; Geoffrey M Anderson
Journal:  Med Care       Date:  2011-10       Impact factor: 2.983

6.  Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes.

Authors:  Julie Hallet; Calvin How Lim Law; Moises Cukier; Refik Saskin; Ning Liu; Simron Singh
Journal:  Cancer       Date:  2014-10-13       Impact factor: 6.860

7.  Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  E C Smyth; M Verheij; W Allum; D Cunningham; A Cervantes; D Arnold
Journal:  Ann Oncol       Date:  2016-09       Impact factor: 32.976

8.  Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.

Authors:  John P Neoptolemos; Daniel H Palmer; Paula Ghaneh; Eftychia E Psarelli; Juan W Valle; Christopher M Halloran; Olusola Faluyi; Derek A O'Reilly; David Cunningham; Jonathan Wadsley; Suzanne Darby; Tim Meyer; Roopinder Gillmore; Alan Anthoney; Pehr Lind; Bengt Glimelius; Stephen Falk; Jakob R Izbicki; Gary William Middleton; Sebastian Cummins; Paul J Ross; Harpreet Wasan; Alec McDonald; Tom Crosby; Yuk Ting Ma; Kinnari Patel; David Sherriff; Rubin Soomal; David Borg; Sharmila Sothi; Pascal Hammel; Thilo Hackert; Richard Jackson; Markus W Büchler
Journal:  Lancet       Date:  2017-01-25       Impact factor: 79.321

9.  Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.

Authors:  René Adam; Valérie Delvart; Gérard Pascal; Adrian Valeanu; Denis Castaing; Daniel Azoulay; Sylvie Giacchetti; Bernard Paule; Francis Kunstlinger; Odile Ghémard; Francis Levi; Henri Bismuth
Journal:  Ann Surg       Date:  2004-10       Impact factor: 12.969

10.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

View more
  1 in total

1.  Less Is More? The Association between Survival and Follow-Up Protocol after Treatment in Oral Cavity Cancer Patients from a Betel Quid-Prevalent Region.

Authors:  Shih-An Liu; Chen-Chi Wang; Rong-San Jiang; Yu-Chi Tung
Journal:  Int J Environ Res Public Health       Date:  2021-11-29       Impact factor: 3.390

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.